Winton Group’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,056
| Closed | -$1.16M | – | 1331 |
|
|
2026
Q1 | $1.16M | Buy |
2,056
+587
| +40% | +$376K | 0.04% | 505 |
|
|
2025
Q4 | $994K | Sell |
1,469
-620
| -30% | -$422K | 0.03% | 487 |
|
|
2025
Q3 | $1.33M | Buy |
+2,089
| New | +$1.27M | 0.05% | 336 |
|
|
2025
Q2 | – | Sell |
-8,314
| Closed | -$3.49M | – | 902 |
|
|
2025
Q1 | $3.49M | Sell |
8,314
-7,186
| -46% | -$3.12M | 0.21% | 113 |
|
|
2024
Q4 | $6.41M | Buy |
+15,500
| New | +$6.8M | 0.43% | 50 |
|
|
2024
Q3 | – | Sell |
-1,260
| Closed | -$614K | – | 704 |
|
|
2024
Q2 | $614K | Sell |
1,260
-94
| -7% | -$47.2K | 0.04% | 397 |
|
|
2024
Q1 | $731K | Buy |
+1,354
| New | +$740K | 0.05% | 404 |
|
|
2023
Q4 | – | Sell |
-937
| Closed | -$410K | – | 793 |
|
|
2023
Q3 | $410K | Sell |
937
-47
| -5% | -$23.4K | 0.03% | 344 |
|
|
2023
Q2 | $494K | Buy |
+984
| New | +$472K | 0.04% | 322 |
|
|
2022
Q1 | – | Sell |
-576
| Closed | -$379K | – | 1052 |
|
|
2021
Q4 | $379K | Sell |
576
-2,896
| -83% | -$1.82M | 0.02% | 759 |
|
|
2021
Q3 | $2.16M | Buy |
3,472
+1,700
| +96% | +$1.14M | 0.12% | 162 |
|
|
2021
Q2 | $1.12M | Sell |
1,772
-181
| -9% | -$99.9K | 0.06% | 466 |
|
|
2021
Q1 | $956K | Sell |
1,953
-358
| -15% | -$179K | 0.05% | 491 |
|
|
2020
Q4 | $1.16M | Sell |
2,311
-5,754
| -71% | -$2.57M | 0.08% | 337 |
|
|
2020
Q3 | $3.17M | Sell |
8,065
-6,003
| -43% | -$2.22M | 0.1% | 305 |
|
|
2020
Q2 | $4.64M | Sell |
14,068
-869
| -6% | -$252K | 0.12% | 245 |
|
|
2020
Q1 | $3.62M | Sell |
14,937
-19,593
| -57% | -$5.11M | 0.1% | 374 |
|
|
2019
Q4 | $9.02M | Buy |
34,530
+4,452
| +15% | +$1.17M | 0.13% | 272 |
|
|
2019
Q3 | $8.18M | Buy |
30,078
+25,068
| +500% | +$6.98M | 0.1% | 257 |
|
|
2019
Q2 | $1.38M | Buy |
5,010
+852
| +20% | +$210K | 0.03% | 341 |
|
|
2019
Q1 | $930K | Sell |
4,158
-2,066
| -33% | -$426K | 0.02% | 361 |
|
|
2018
Q4 | $1.16M | Buy |
6,224
+774
| +14% | +$159K | 0.02% | 329 |
|
|
2018
Q3 | $1.36M | Buy |
5,450
+320
| +6% | +$77.7K | 0.03% | 350 |
|
|
2018
Q2 | $1.12M | Sell |
5,130
-6,676
| -57% | -$1.38M | 0.03% | 404 |
|
|
2018
Q1 | $2.26M | Sell |
11,806
-6,211
| -34% | -$1.15M | 0.06% | 311 |
|
|
2017
Q4 | $2.82M | Sell |
18,017
-6,036
| -25% | -$950K | 0.08% | 343 |
|
|
2017
Q3 | $3.74M | Buy |
24,053
+20,772
| +633% | +$3.28M | 0.12% | 199 |
|
|
2017
Q2 | $530K | Sell |
3,281
-572
| -15% | -$92.9K | 0.02% | 493 |
|
|
2017
Q1 | $596K | Buy |
+3,853
| New | +$531K | 0.02% | 359 |
|
|
2016
Q4 | – | Sell |
-172,391
| Closed | -$19.4M | – | 465 |
|
|
2016
Q3 | $19.4M | Buy |
172,391
+1,717
| +1% | +$181K | 0.33% | 115 |
|
|
2016
Q2 | $15.8M | Buy |
+170,674
| New | +$14.7M | 0.26% | 147 |
|
|
2015
Q4 | – | Sell |
-210,210
| Closed | -$15.6M | – | 337 |
|
|
2015
Q3 | $15.6M | Buy |
210,210
+168,644
| +406% | +$12.1M | 0.12% | 262 |
|
|
2015
Q2 | $2.67M | Sell |
41,566
-124,264
| -75% | -$8.6M | 0.02% | 337 |
|
|
2015
Q1 | $12.8M | Sell |
165,830
-56,864
| -26% | -$4.43M | 0.1% | 271 |
|
|
2014
Q4 | $16.5M | Sell |
222,694
-101,798
| -31% | -$7.14M | 0.2% | 189 |
|
|
2014
Q3 | $19.1M | Sell |
324,492
-97,854
| -23% | -$6.19M | 0.14% | 261 |
|
|
2014
Q2 | $28.2M | Buy |
+422,346
| New | +$26.9M | 0.19% | 219 |
|
Other funds holding IDXX
VCM
VPM
Winton Group's IDXX Position: Q2 2026 in Review
Winton Group sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 2,056 shares — an estimated $1.16M sold.
Winton Group first reported a position in IDXX in Q2 2014 and held it in 37 quarters. The position peaked at $28.2M in Q2 2014. 1,046 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Winton Group reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
- Winton Group sold 2,056 Idexx Laboratories shares in Q2 2026, an estimated $1.16M.
- Winton Group first reported a position in Idexx Laboratories in Q2 2014 and held it in 37 quarters.
- Winton Group's Idexx Laboratories position peaked at $28.2M in Q2 2014.
- 1,046 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.